PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+29.36%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.46%
AUM
$3.44B
AUM Growth
+$3.44B
(+8.1%)
Cap. Flow
+$258M
Cap. Flow
% of AUM
7.49%
Top 10 Holdings %
Top 10 Hldgs %
43.94%
Holding
127
New
15
Increased
25
Reduced
25
Closed
9
Top Buys
| 1 |
Relmada Therapeutics
RLMD
|
$83.7M |
| 2 |
Amylyx Pharmaceuticals
AMLX
|
$54.4M |
| 3 |
BLU
BELLUS Health Inc.
BLU
|
$49.8M |
| 4 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$40.3M |
| 5 |
CINC
CinCor Pharma, Inc. Common Stock
CINC
|
$32.4M |
Top Sells
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$47.2M |
| 2 |
Eli Lilly
LLY
|
$32.4M |
| 3 |
Neurocrine Biosciences
NBIX
|
$31.6M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$25.2M |
| 5 |
Procept Biorobotics
PRCT
|
$20.1M |
Sector Composition
| 1 | Healthcare | 97.83% |
| 2 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
RAPT Therapeutics
RAPT
$187M
| $41.2M | 1.2% |
1,713,134
-200,657
| -10% | -$4.83M |
|
|
VBIV
27
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $37.2M | 1.08% |
52,335,002
| – | – |
|
28
Treace Medical Concepts
TMCI
$458M
| $35.4M | 1.03% |
1,601,979
+660,787
| +70% | +$14.6M |
|
29
Nuvalent
NUVL
$5.74B
| $32.2M | 0.93% |
1,655,007
| – | – |
|
30
Establishment Labs
ESTA
$1.11B
| $31.6M | 0.92% |
578,253
+172,494
| +43% | +$9.42M |
|
31
BioMarin Pharmaceuticals
BMRN
$11.3B
| $28.5M | 0.83% |
336,481
+156,481
| +87% | +$13.3M |
|
32
Sarepta Therapeutics
SRPT
$1.98B
| $28M | 0.81% |
+253,000
| New | +$28M |
|
33
Edwards Lifesciences
EW
$47.7B
| $27.3M | 0.79% |
+330,000
| New | +$27.3M |
|
34
Zymeworks
ZYME
$1.07B
| $27.1M | 0.79% |
4,400,099
+267,565
| +6% | +$1.65M |
|
35
ADMA Biologics
ADMA
$4.03B
| $26.6M | 0.77% |
10,933,387
-587,715
| -5% | -$1.43M |
|
36
Viridian Therapeutics
VRDN
$1.59B
| $25M | 0.73% |
1,220,575
+248,743
| +26% | +$5.1M |
|
37
Apellis Pharmaceuticals
APLS
$3.51B
| $25M | 0.73% |
366,400
+45,100
| +14% | +$3.08M |
|
38
Immatics
IMTX
$662M
| $25M | 0.73% |
2,500,000
| – | – |
|
|
CMAX
39
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $24.1M | 0.7% |
3,394,939
+394,939
| +13% | +$2.8M |
|
40
Tarsus Pharmaceuticals
TARS
$2.44B
| $22.2M | 0.64% |
1,296,416
| – | – |
|
|
RVNC
41
DELISTED
Revance Therapeutics, Inc.
RVNC
| $21.8M | 0.63% |
808,671
+236,157
| +41% | +$6.38M |
|
42
Madrigal Pharmaceuticals
MDGL
$9.7B
| $21.5M | 0.62% |
331,023
-36,478
| -10% | -$2.37M |
|
43
Nautilus Biotechnolgy
NAUT
$80.7M
| $19.3M | 0.56% |
9,111,151
| – | – |
|
44
Cytek Biosciences
CTKB
$501M
| $19M | 0.55% |
+1,289,534
| New | +$19M |
|
45
Outset Medical
OM
$245M
| $18.6M | 0.54% |
1,168,630
+169,903
| +17% | +$2.71M |
|
|
ISEE
46
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $18.6M | 0.54% |
1,034,169
-1,053,787
| -50% | -$18.9M |
|
47
Harmony Biosciences
HRMY
$2.16B
| $18.2M | 0.53% |
411,804
| – | – |
|
48
Arcus Biosciences
RCUS
$1.24B
| $17.4M | 0.51% |
+666,477
| New | +$17.4M |
|
49
BridgeBio Pharma
BBIO
$9.91B
| $16.9M | 0.49% |
1,697,033
| – | – |
|
50
Artivion
AORT
$2.04B
| $16.7M | 0.48% |
1,204,229
+274,524
| +30% | +$3.8M |
|